Noubar B. Afeyan Ph.D.
Net Worth
Last updated:
What is Noubar B. Afeyan Ph.D. net worth?
The estimated net worth of Dr. Noubar B. Afeyan Ph.D. is at least $956,593,783 as of 31 Jul 2024. He owns shares worth $61,716,416 as insider, has earned $894,447,367 from insider trading and has received compensation worth at least $430,000 in Moderna, Inc..
What is the salary of Noubar B. Afeyan Ph.D.?
Dr. Noubar B. Afeyan Ph.D. salary is $107,500 per year as Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board in Moderna, Inc..
How old is Noubar B. Afeyan Ph.D.?
Dr. Noubar B. Afeyan Ph.D. is 62 years old, born in 1963.
What stocks does Noubar B. Afeyan Ph.D. currently own?
As insider, Dr. Noubar B. Afeyan Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Moderna, Inc. (MRNA) | Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board | 2,224,015 | $27.75 | $61,716,416 |
What does Moderna, Inc. do?
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Noubar B. Afeyan Ph.D. insider trading
Moderna, Inc.
Dr. Noubar B. Afeyan Ph.D. has made 146 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,309 units of MRNA stock worth $159,205 on 31 Jul 2024.
The largest trade he's ever made was exercising 2,947,638 units of MRNA stock on 23 Feb 2021. As of 31 Jul 2024 he still owns at least 2,224,015 units of MRNA stock.
Moderna key executives
Moderna, Inc. executives and other stock owners filed with the SEC:
- Dr. Noubar B. Afeyan Ph.D. (62) Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board
- Dr. Stephen Hoge (49) Pres
- Mr. David W. Meline (68) Chief Financial Officer & Principal Accounting Officer
- Mr. Juan Andres (60) Chief Technical Operations & Quality Officer
- Mr. Stephane Bancel (52) Chief Executive Officer & Director